
CLAIMS

1. A therapeutically effective amount of a composition comprising (i) a dual PI3K delta and gamma inhibitor, and (ii) a corticosteroid, for use in the treatment of an autoimmune, respiratory and/or inflammatory disease or condition, wherein

the therapeutically effective amount of (i) a dual PI3K delta and gamma inhibitor, and (ii) a corticosteroid is to be administered to a subject in need thereof, and


the dual PI3K delta and gamma inhibitor is a compound of formula A:



Formula A

or a pharmaceutically acceptable salt thereof.

2. Use of a therapeutically effective amount of (i) a dual PI3K delta and gamma inhibitor, and (ii) a corticosteroid in the manufacture of a medicament for the treatment of an autoimmune, respiratory and/or inflammatory disease or condition, wherein the dual PI3K delta and gamma inhibitor is a compound of formula A:



Formula A

or a pharmaceutically acceptable salt thereof.

3. The use according to claim 2, wherein the corticosteroid is selected from the group consisting of dexamethasone, betamethasone, prednisolone, methyl prednisolone, prednisone, hydrocortisone, fluticasone, triamcinolone, budesonide, cortisone prednisolone, methylprednisolone, naflocort, deflazacort, halopredone acetate, beclomethasone dipropionate, hydrocortisone, triamcinolone acetonide, fluocinolone acetonide, fluocinonide, clocortolone pivalate, methylprednisolone aceponate, dexamethasone palmitoate, tipredane, hydrocortisone aceponate, prednicarbate, alclometasone dipropionate, halometasone, methylprednisolone suleptanate, mometasone furoate, rimexolone, prednisolone farnesylate, ciclesonide, deprodone propionate, fluticasone propionate, halobetasol propionate, loteprednol etabonate, betamethasone butyrate propionate, flunisolide, prednisone, dexamethasone sodium phosphate, triamcinolone, betamethasone 17-valerate, betamethasone, betamethasone dipropionate, hydrocortisone acetate, hydrocortisone sodium succinate, prednisolone sodium phosphate, hydrocortisone probutate, and pharmaceutically acceptable salts thereof.

4. The use according to claim 2, wherein the corticosteroid is selected from the group consisting of mometasone furoate, dexamethasone, betamethasone, prednisolone, methyl prednisolone, prednisone, hydrocortisone, fluticasone, triamcinolone, budesonide, cortisone, and pharmaceutically acceptable salts thereof.

5. The use according to claim 2, wherein the corticosteroid is selected from mometasone furoate, dexamethasone, fluticasone, and pharmaceutically acceptable salts thereof.

6. The use according to claim 2, wherein the therapeutically effective amount of (i) the dual PI3K delta and gamma inhibitor, and the therapeutically effective amount of (ii) a corticosteroid are to be administered simultaneously as a combined formulation.

7. The use according to claim 2, wherein the therapeutically effective amount of (i) the dual PI3K delta and gamma inhibitor, and the therapeutically effective amount of (ii) a corticosteroid are to be administered sequentially.

8. The use according to claim 2, wherein the therapeutically effective amount of the corticosteroid is to be administered before the therapeutically effective amount of the dual PI3K delta and gamma inhibitor.

9. The use according to claim 2, wherein the therapeutically effective amount of the dual PI3K delta and gamma inhibitor is to be administered twice daily to once every three weeks, and the therapeutically effective amount of the corticosteroid is to be administered twice daily to once every three weeks.


10. The use according to claim 2, wherein the autoimmune, respiratory and/or inflammatory disease or condition is selected from the group consisting of asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel disease, glomerulonephritis, neuro inflammatory diseases, multiple sclerosis, uveitis, psoriasis, arthritis, vasculitis, dermatitis, osteoarthritis, inflammatory muscle disease, allergic rhinitis, vaginitis, interstitial cystitis, scleroderma, osteoporosis, eczema, allogeneic or xenogeneic transplantation (organ, bone marrow, stem cells and other cells and tissues) graft rejection, graft-versus-host disease, lupus erythematosus, inflammatory disease, type I diabetes, pulmonary fibrosis, dermatomyositis, Sjogren's syndrome, thyroiditis, myasthenia gravis, autoimmune hemolytic anemia, cystic fibrosis, idiopathic pulmonary fibrosis (IPF), chronic relapsing hepatitis, primary biliary cirrhosis, allergic conjunctivitis, atopic dermatitis, and combinations thereof.

11. The use according to claim 2, wherein the autoimmune, respiratory and/or inflammatory disease or condition is selected from the group consisting of asthma, allergic rhinitis, non-allergic rhinitis, rheumatoid arthritis, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis (IPF) and atopic dermatitis.

12. The use according to claim 2, wherein the dual PI3K delta and gamma inhibitor and the corticosteroid are each to be administered in an amount ranging from 0.01 mg to 1000 mg.

13. The use according to claim 2, wherein the dual PI3K delta and gamma inhibitor and the corticosteroid are to be administered at a ratio of 1:100 to 100:1 by weight.

14. A pharmaceutical composition comprising (i) a dual PI3K delta and gamma inhibitor, (ii) a corticosteroid, and (iii) optionally, a pharmaceutically acceptable carrier, glidant, diluent, or excipient, wherein the dual PI3K delta and gamma inhibitor is a compound of formula A:



Formula A

or a pharmaceutically acceptable salt thereof.

15. The pharmaceutical composition according to claim 14, wherein the corticosteroid is selected from the group consisting of dexamethasone, betamethasone, prednisolone, methyl prednisolone, prednisone, hydrocortisone, fluticasone, triamcinolone, budesonide, cortisone prednisolone, methylprednisolone, naflocort, deflazacort, halopredone acetate, beclomethasone dipropionate, hydrocortisone, triamcinolone acetonide, fluocinolone acetonide, fluocinonide, clocortolone pivalate, methylprednisolone aceponate, dexamethasone palmitoate, tipredane, hydrocortisone aceponate, prednicarbate, alclometasone dipropionate, halometasone, methylprednisolone suleptanate, mometasone furoate, rimexolone, prednisolone farnesylate, ciclesonide, deprodone propionate, fluticasone propionate, halobetasol propionate, loteprednol etabonate, betamethasone butyrate propionate, flunisolide, prednisone, dexamethasone sodium phosphate, triamcinolone, betamethasone 17-valerate, betamethasone, betamethasone dipropionate, hydrocortisone acetate, hydrocortisone sodium succinate, prednisolone sodium phosphate, hydrocortisone probutate, and pharmaceutically acceptable salts thereof.

16. The pharmaceutical composition according to any one of claims 14-15, wherein the corticosteroid is selected from the group consisting of mometasone furoate, dexamethasone, betamethasone, prednisolone, methyl prednisolone, prednisone, hydrocortisone, fluticasone, triamcinolone, budesonide, cortisone, and pharmaceutically acceptable salts thereof.

17. The pharmaceutical composition according to any one of claims 14-16, wherein the corticosteroid is selected from dexamethasone, fluticasone, and pharmaceutically acceptable salts thereof.

18. The pharmaceutical composition of any one of claims 14-17, wherein the composition comprises 0.01 mg to 1000 mg of the dual PI3K delta and gamma inhibitor and 0.01 mg to 1000 mg of the corticosteroid.

19. The pharmaceutical composition according to any one of claims 14-18, for use in the treatment of an autoimmune, respiratory and/or inflammatory disease or condition selected from the group consisting of asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel disease, glomerulonephritis, neuroinflammatory diseases, multiple sclerosis, uveitis, psoriasis, arthritis, vasculitis, dermatitis, osteoarthritis, inflammatory muscle disease, allergic rhinitis, vaginitis, interstitial cystitis, scleroderma, osteoporosis, eczema, allogeneic or xenogeneic transplantation (organ, bone marrow, stem cells and other cells and tissues) graft rejection, graft-versus-host disease, lupus erythematosus, inflammatory disease, type I diabetes, pulmonary fibrosis, dermatomyositis, Sjogren's syndrome, thyroiditis (e.g., Hashimoto's and autoimmune thyroiditis), myasthenia gravis, autoimmune hemolytic anemia, cystic fibrosis, Idiopathic pulmonary fibrosis (IPF), chronic relapsing hepatitis, primary biliary cirrhosis, allergic conjunctivitis and atopic dermatitis, and combinations thereof.

20. The use of a pharmaceutical composition according to any one of claims 14-18 in the manufacture of a medicament for the treatment of an autoimmune, respiratory and/or inflammatory disease or condition selected from the group consisting of asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel disease, glomerulonephritis, neuroinflammatory diseases, multiple sclerosis, uveitis, psoriasis, arthritis, vasculitis, dermatitis, osteoarthritis, inflammatory muscle disease, allergic rhinitis, vaginitis, interstitial cystitis, scleroderma, osteoporosis, eczema, allogeneic or xenogeneic transplantation (organ, bone marrow, stem cells and other cells and tissues) graft rejection, graft-versus-host disease, lupus erythematosus, inflammatory disease, type I diabetes, pulmonary fibrosis, dermatomyositis, Sjogren's syndrome, thyroiditis (e.g., Hashimoto's and autoimmune thyroiditis), myasthenia gravis, autoimmune hemolytic anemia, cystic fibrosis, Idiopathic pulmonary fibrosis (IPF), chronic relapsing hepatitis, primary biliary cirrhosis, allergic conjunctivitis and atopic dermatitis, and combinations thereof.


21. A kit for use in the treatment of an autoimmune, respiratory or inflammatory disease or condition, the kit comprising:

(i) a dual PI3K delta and gamma inhibitor, and (ii) a corticosteroid, or a pharmaceutically acceptable salt thereof, in a single pharmaceutical composition,

(ii) instructions for treating the autoimmune, respiratory or inflammatory disease or condition with the dual PI3K delta and gamma inhibitor and corticosteroid and

(iii) a container for placing the pharmaceutical composition,

wherein the dual PI3K delta and gamma inhibitor is a compound of formula A:



Formula A

or a pharmaceutically acceptable salt thereof.


22. Use of a kit in the manufacture of a medicament for the treatment of an autoimmune, respiratory or inflammatory disease or condition selected from the group consisting of asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel disease, glomerulonephritis, neuroinflammatory diseases, multiple sclerosis, uveitis, psoriasis, arthritis, vasculitis, dermatitis, osteoarthritis, inflammatory muscle disease, allergic rhinitis, vaginitis, interstitial cystitis, scleroderma, osteoporosis, eczema, allogeneic or xenogeneic transplantation (organ, bone marrow, stem cells and other cells and tissues) graft rejection, graft-versus-host disease, lupus erythematosus, inflammatory disease, type I diabetes, pulmonary fibrosis, dermatomyositis, Sjogren's syndrome, thyroiditis (e.g., Hashimoto's and autoimmune thyroiditis), myasthenia gravis, autoimmune hemolytic anemia, cystic fibrosis, Idiopathic pulmonary fibrosis (IPF), chronic relapsing hepatitis, primary biliary cirrhosis, allergic conjunctivitis and atopic dermatitis, the kit comprising:

(i) a dual PI3K delta and gamma inhibitor, and (ii) a corticosteroid, or a pharmaceutically acceptable salt thereof, in a single pharmaceutical composition,

(ii) instructions for treating the autoimmune, respiratory or inflammatory disease or condition with the dual PI3K delta and gamma inhibitor and corticosteroid and

(iii) a container for placing the pharmaceutical composition,

wherein the dual PI3K delta and gamma inhibitor is a compound of formula A:



Formula A

or a pharmaceutically acceptable salt thereof.